Next Article in Journal
An Evaluation of Total Internal Motions of Locally Advanced Pancreatic Cancer during SABR Using Calypso® Extracranial Tracking, and Its Possible Clinical Impact on Motion Management
Previous Article in Journal
PD-1 Inhibitor Maintenance Therapy Combined Iodine-125 Seed Implantation Successfully Salvage Recurrent Cervical Cancer after CCRT: A Case Report
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 28
Issue 6
10.3390/curroncol28060388
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden

by
Nai-Wen Kang
1,
Kien-Thiam Tan
2,
Chien-Feng Li
3,4 and
Yu-Hsuan Kuo
1,5,*
1
Division of Hematology and Oncology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan 71004, Taiwan
2
ACT Genomics Co., Ltd., Taipei 114, Taiwan
3
Department of Medical Research, Chi-Mei Medical Center, Tainan 71004, Taiwan
4
National Institute of Cancer Research, National Health Research Institutes, Tainan 70456, Taiwan
5
College of Pharmacy and Science, Chia Nan University, Tainan 71710, Taiwan
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(6), 4587-4596; https://doi.org/10.3390/curroncol28060388
Submission received: 19 October 2021 / Revised: 6 November 2021 / Accepted: 7 November 2021 / Published: 10 November 2021
Browse Figures
Review Reports Versions Notes

Abstract

Poorly differentiated pancreatic neuroendocrine carcinomas (NECs) are rare and aggressive malignancies with rapid disease progression and early widespread metastasis. Given histology similarity, they are commonly treated with platinum-based chemotherapy as small cell lung cancer (SCLC). However, no standard treatment has been established for recurrent or progressive disease. We present an Asian patient with recurrent poorly differentiated pancreatic NEC after curative surgery and adjuvant chemotherapy with cisplatin and etoposide. The tumor mutational burden (TMB) was high. The patient received chemotherapy combined with maintenance immunotherapy with nivolumab and achieved promising and durable response, suggesting TMB could be a biomarker to identify NEC patients for immune checkpoint inhibitor (ICI) treatment.
Keywords: neuroendocrine carcinoma; immunotherapy; immune checkpoint inhibitor; tumor mutational burden neuroendocrine carcinoma; immunotherapy; immune checkpoint inhibitor; tumor mutational burden

Share and Cite

MDPI and ACS Style

Kang, N.-W.; Tan, K.-T.; Li, C.-F.; Kuo, Y.-H. Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden. Curr. Oncol. 2021, 28, 4587-4596. https://doi.org/10.3390/curroncol28060388

AMA Style

Kang N-W, Tan K-T, Li C-F, Kuo Y-H. Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden. Current Oncology. 2021; 28(6):4587-4596. https://doi.org/10.3390/curroncol28060388

Chicago/Turabian Style

Kang, Nai-Wen, Kien-Thiam Tan, Chien-Feng Li, and Yu-Hsuan Kuo. 2021. "Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden" Current Oncology 28, no. 6: 4587-4596. https://doi.org/10.3390/curroncol28060388

APA Style

Kang, N.-W., Tan, K.-T., Li, C.-F., & Kuo, Y.-H. (2021). Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden. Current Oncology, 28(6), 4587-4596. https://doi.org/10.3390/curroncol28060388

Article Metrics

Back to TopTop